{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:24:20Z","timestamp":1792041860388,"version":"4.4.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["U54 MD007582"],"award-info":[{"award-number":["U54 MD007582"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100028779","name":"Consortium for Medical Marijuana Clinical Outcomes Research","doi-asserted-by":"publisher","award":["SUB00002097"],"award-info":[{"award-number":["SUB00002097"]}],"id":[{"id":"10.13039\/100028779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s13346-026-02057-1","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:23:10Z","timestamp":1770819790000},"page":"3534-3554","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacokinetic studies and synergistic antitumor effects of cannabichromene and cannabidiol in drug-resistant breast cancers"],"prefix":"10.1007","volume":"16","author":[{"given":"Mounika","family":"Aare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep Chary","family":"Padakanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jassy Mary","family":"Lazarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyanarayan","family":"Dev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandip","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"2","key":"2057_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.20517\/cdr.2019.10","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist. 2019;2(2):141\u201360. https:\/\/doi.org\/10.20517\/cdr.2019.10.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"2057_CR2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/CAD.0b013e3280101006","volume":"18","author":"SV Fulzele","year":"2007","unstructured":"Fulzele SV, Chatterjee A, Shaik MS, Jackson T, Ichite N, Singh M. 15-deoxy-\u039412,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors. Anticancer Drugs. 2007;18(1):65. https:\/\/doi.org\/10.1097\/CAD.0b013e3280101006.","journal-title":"Anticancer Drugs"},{"issue":"11","key":"2057_CR3","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2217\/nnm.16.37","volume":"11","author":"K Patel","year":"2016","unstructured":"Patel K, Doddapaneni R, Chowdhury N, Boakye CH, Behl G, Singh M. Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomedicine. 2016;11(11):1377\u201392. https:\/\/doi.org\/10.2217\/nnm.16.37.","journal-title":"Nanomedicine"},{"issue":"9","key":"2057_CR4","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.21873\/anticanres.15226","volume":"41","author":"SK Surapaneni","year":"2021","unstructured":"Surapaneni SK, et al. Telmisartan facilitates the anticancer effects of CARP-1 functional mimetic and sorafenib in rociletinib resistant non-small cell lung cancer. Anticancer Res. 2021;41(9):4215\u201328. https:\/\/doi.org\/10.21873\/anticanres.15226.","journal-title":"Anticancer Res"},{"key":"2057_CR5","unstructured":"Udofot O, et al. Pharmacokinetic, biodistribution and therapeutic efficacy of 5-fluorouracil-loaded pH-sensitive PEGylated liposomal nanoparticles in HCT-116 tumor bearing mouse. J Nat Sci. 2016;2(1):e171. Accessed 16 Jan 2024. [Online]. Available: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4869888\/."},{"issue":"6","key":"2057_CR6","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1021\/acs.molpharmaceut.6b00187","volume":"13","author":"K Patel","year":"2016","unstructured":"Patel K, Doddapaneni R, Sekar V, Chowdhury N, Singh M. Combination approach of YSA peptide anchored docetaxel stealth liposomes with oral antifibrotic agent for the treatment of lung cancer. Mol Pharm. 2016;13(6):2049\u201358. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00187.","journal-title":"Mol Pharm"},{"key":"2057_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1730-1","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019. https:\/\/doi.org\/10.1038\/s41586-019-1730-1.","journal-title":"Nature"},{"issue":"1","key":"2057_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-015-0221-1","volume":"15","author":"KO Alfarouk","year":"2015","unstructured":"Alfarouk KO, et al. Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp. Cancer Cell Int. 2015;15(1):71. https:\/\/doi.org\/10.1186\/s12935-015-0221-1.","journal-title":"Cancer Cell Int"},{"key":"2057_CR9","doi-asserted-by":"crossref","unstructured":"Emran TB, et al. Multidrug resistance in cancer: Understanding molecular mechanisms, immunoprevention and therapeutic approaches. Front Oncol. 2022;12. Accessed 16 Jan 2024. [Online]. Available: https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.891652.","DOI":"10.3389\/fonc.2022.891652"},{"key":"2057_CR10","unstructured":"O\u2019connor R. The pharmacology of cancer resistance. Anticancer Res. 2007;27(3A):1267\u20131272. Accessed 31 Dec 2023. [Online]. Available: https:\/\/ar.iiarjournals.org\/content\/27\/3A\/1267."},{"issue":"1","key":"2057_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0587-8","volume":"11","author":"W Si","year":"2019","unstructured":"Si W, Shen J, Zheng H, Fan W. The role and mechanisms of action of micrornas in cancer drug resistance. Clin Epigenetics. 2019;11(1):25. https:\/\/doi.org\/10.1186\/s13148-018-0587-8.","journal-title":"Clin Epigenetics"},{"issue":"9","key":"2057_CR12","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<1986::AID-CNCR2>3.0.CO;2-I","volume":"88","author":"Y-H Chung","year":"2000","unstructured":"Chung Y-H, et al. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-\u03b1 for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer. 2000;88(9):1986\u201391. https:\/\/doi.org\/10.1002\/(SICI)1097-0142(20000501)88:9%3c1986::AID-CNCR2%3e3.0.CO;2-I.","journal-title":"Cancer"},{"issue":"1","key":"2057_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canlet.2007.09.015","volume":"259","author":"SH Lee","year":"2008","unstructured":"Lee SH, et al. Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer. Cancer Lett. 2008;259(1):39\u201349. https:\/\/doi.org\/10.1016\/j.canlet.2007.09.015.","journal-title":"Cancer Lett"},{"key":"2057_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00092","volume":"8","author":"A Suraweera","year":"2018","unstructured":"Suraweera A, O\u2019Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol. 2018;8:92. https:\/\/doi.org\/10.3389\/fonc.2018.00092.","journal-title":"Front Oncol"},{"issue":"1","key":"2057_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0014-2999(98)00392-6","volume":"353","author":"S Ben-Shabat","year":"1998","unstructured":"Ben-Shabat S, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998;353(1):23\u201331. https:\/\/doi.org\/10.1016\/S0014-2999(98)00392-6.","journal-title":"Eur J Pharmacol"},{"key":"2057_CR16","doi-asserted-by":"crossref","unstructured":"Russo EB. The case for the entourage effect and conventional breeding of clinical cannabis: No \u2018Strain,\u2019 No Gain. Front Plant Sci. 2019;9. Accessed 16 Jan 2024. [Online]. Available: https:\/\/www.frontiersin.org\/articles\/10.3389\/fpls.2018.01969","DOI":"10.3389\/fpls.2018.01969"},{"key":"2057_CR17","doi-asserted-by":"crossref","unstructured":"Pertwee RG. Handbook of Cannabis. Oxford University Press, 2014.","DOI":"10.1093\/acprof:oso\/9780199662685.001.0001"},{"issue":"2","key":"2057_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1158\/0008-5472.CAN-07-2785","volume":"68","author":"S Sarfaraz","year":"2008","unstructured":"Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res. 2008;68(2):339\u201342. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-2785.","journal-title":"Cancer Res"},{"issue":"3","key":"2057_CR19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/jnci\/55.3.597","volume":"55","author":"AE Munson","year":"1975","unstructured":"Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. Antineoplastic activity of cannabinoids2. JNCI J Natl Cancer Inst. 1975;55(3):597\u2013602. https:\/\/doi.org\/10.1093\/jnci\/55.3.597.","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"14","key":"2057_CR20","doi-asserted-by":"publisher","first-page":"2633","DOI":"10.1096\/fj.06-6638fje","volume":"20","author":"C Bl\u00e1zquez","year":"2006","unstructured":"Bl\u00e1zquez C, et al. \u201cCannabinoid receptors as novel targets for the treatment of melanoma.\u201d FASEB J. 2006;20(14):2633\u20135. https:\/\/doi.org\/10.1096\/fj.06-6638fje.","journal-title":"FASEB J"},{"issue":"13","key":"2057_CR21","doi-asserted-by":"publisher","first-page":"6748","DOI":"10.1158\/0008-5472.CAN-06-0169","volume":"66","author":"A Carracedo","year":"2006","unstructured":"Carracedo A, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res. 2006;66(13):6748\u201355. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-0169.","journal-title":"Cancer Res"},{"issue":"3","key":"2057_CR22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/sj.onc.1210641","volume":"27","author":"A Preet","year":"2008","unstructured":"Preet A, Ganju RK, Groopman JE. \u03949-tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene. 2008;27(3):339\u201346. https:\/\/doi.org\/10.1038\/sj.onc.1210641.","journal-title":"Oncogene"},{"issue":"2","key":"2057_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/sj.bjc.6603236","volume":"95","author":"M Guzm\u00e1n","year":"2006","unstructured":"Guzm\u00e1n M, et al. A pilot clinical study of \u03949-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197\u2013203. https:\/\/doi.org\/10.1038\/sj.bjc.6603236.","journal-title":"Br J Cancer"},{"issue":"17","key":"2057_CR24","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s00018-006-6156-x","volume":"63","author":"P Massi","year":"2006","unstructured":"Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci. 2006;63(17):2057\u201366. https:\/\/doi.org\/10.1007\/s00018-006-6156-x.","journal-title":"Cell Mol Life Sci"},{"key":"2057_CR25","doi-asserted-by":"crossref","unstructured":"Walsh KB, McKinney AE, Holmes AE. Minor cannabinoids: biosynthesis, molecular pharmacology and potential therapeutic uses. Front Pharmacol. 2021;12. Accessed 31 Dec 2023. [Online]. Available: https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.777804.","DOI":"10.3389\/fphar.2021.777804"},{"key":"2057_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.biochi.2022.12.008","volume":"208","author":"AK Kalvala","year":"2023","unstructured":"Kalvala AK, et al. The role of cannabidiol and tetrahydrocannabivarin to overcome doxorubicin resistance in MDA-MB-231 xenografts in athymic nude mice. Biochimie. 2023;208:19\u201330. https:\/\/doi.org\/10.1016\/j.biochi.2022.12.008.","journal-title":"Biochimie"},{"issue":"2","key":"2057_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s13105-018-0611-7","volume":"74","author":"BM Fonseca","year":"2018","unstructured":"Fonseca BM, Correia-da-Silva G, Teixeira NA. Cannabinoid-induced cell death in endometrial cancer cells: involvement of TRPV1 receptors in apoptosis. J Physiol Biochem. 2018;74(2):261\u201372. https:\/\/doi.org\/10.1007\/s13105-018-0611-7.","journal-title":"J Physiol Biochem"},{"issue":"4","key":"2057_CR28","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/2472630319854337","volume":"24","author":"P Baillargeon","year":"2019","unstructured":"Baillargeon P, et al. Automating a magnetic 3D spheroid model technology for high-throughput screening. SLAS Technology. 2019;24(4):420\u20138. https:\/\/doi.org\/10.1177\/2472630319854337.","journal-title":"SLAS Technology"},{"key":"2057_CR29","doi-asserted-by":"publisher","first-page":"020025","DOI":"10.1063\/1.5125529","volume":"2155","author":"M Abdullah","year":"2019","unstructured":"Abdullah M, et al. Establishment of primary 3D cell culture based on magnetic bioprinting for colorectal cancer cells from patients in Cipto Mangunkusumo National Hospital Indonesia. AIP Conf Proc. 2019;2155:020025. https:\/\/doi.org\/10.1063\/1.5125529.","journal-title":"AIP Conf Proc"},{"key":"2057_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120943","volume":"607","author":"N Patel","year":"2021","unstructured":"Patel N, et al. Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models. Int J Pharm. 2021;607:120943. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120943.","journal-title":"Int J Pharm"},{"key":"2057_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2021.105290","volume":"115","author":"H Zhang","year":"2021","unstructured":"Zhang H, et al. Anticancer effect evaluation in vitro and in vivo of iridium(III) polypyridyl complexes targeting DNA and mitochondria. Bioorg Chem. 2021;115:105290. https:\/\/doi.org\/10.1016\/j.bioorg.2021.105290.","journal-title":"Bioorg Chem"},{"key":"2057_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.molliq.2025.127161","volume":"426","author":"M Vats","year":"2025","unstructured":"Vats M, Rathod D, Patel H, Richards T, Patel K. Self-emulsifying nano-PND oral delivery systems of PND1186: in silico modeling for bioavailability estimation. J Mol Liq. 2025;426:127161. https:\/\/doi.org\/10.1016\/j.molliq.2025.127161.","journal-title":"J Mol Liq"},{"issue":"4","key":"2057_CR33","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/jat.4409","volume":"43","author":"Y Liu","year":"2023","unstructured":"Liu Y, Sprando RL. Physiologically based pharmacokinetic modeling and simulation of cannabinoids in human plasma and tissues. J Appl Toxicol. 2023;43(4):589\u201398. https:\/\/doi.org\/10.1002\/jat.4409.","journal-title":"J Appl Toxicol"},{"issue":"1","key":"2057_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010263","volume":"22","author":"P \u015aledzi\u0144ski","year":"2020","unstructured":"\u015aledzi\u0144ski P, Nowak-Terpi\u0142owska A, Zeyland J. Cannabinoids in medicine: cancer, immunity, and microbial diseases. Int J Mol Sci. 2020;22(1):263. https:\/\/doi.org\/10.3390\/ijms22010263.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2057_CR35","first-page":"4373","volume":"33","author":"KA Scott","year":"2013","unstructured":"Scott KA, Shah S, Dalgleish AG, Liu WM. Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to drug combinations and treatment schedules. Anticancer Res. 2013;33(10):4373\u201380.","journal-title":"Anticancer Res"},{"issue":"21","key":"2057_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/nu14214548","volume":"14","author":"J-G Mun","year":"2022","unstructured":"Mun J-G, et al. Supercritical extract of Cannabis sativa inhibits lung metastasis in colorectal cancer cells by increasing ampk and mapks-mediated apoptosis and cell cycle arrest. Nutrients. 2022;14(21):4548. https:\/\/doi.org\/10.3390\/nu14214548.","journal-title":"Nutrients"},{"issue":"1","key":"2057_CR37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1089\/can.2018.0010","volume":"3","author":"R Nallathambi","year":"2018","unstructured":"Nallathambi R, et al. Identification of synergistic interaction between cannabis-derived compounds for cytotoxic activity in colorectal cancer cell lines and colon polyps that induces apoptosis-related cell death and distinct gene expression. Cannabis Cannabinoid Res. 2018;3(1):120\u201335. https:\/\/doi.org\/10.1089\/can.2018.0010.","journal-title":"Cannabis Cannabinoid Res"},{"key":"2057_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","volume":"67","author":"IA Mayer","year":"2016","unstructured":"Mayer IA, Arteaga CL. The PI3K\/AKT pathway as a target for cancer treatment. Annu Rev Med. 2016;67:11\u201328. https:\/\/doi.org\/10.1146\/annurev-med-062913-051343.","journal-title":"Annu Rev Med"},{"issue":"31","key":"2057_CR39","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1200\/JCO.2014.59.0018","volume":"34","author":"PM LoRusso","year":"2016","unstructured":"LoRusso PM. Inhibition of the PI3K\/AKT\/mTOR pathway in solid tumors. J Clin Oncol. 2016;34(31):3803\u201315. https:\/\/doi.org\/10.1200\/JCO.2014.59.0018.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2057_CR40","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","volume":"28","author":"KD Courtney","year":"2010","unstructured":"Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075\u201383. https:\/\/doi.org\/10.1200\/JCO.2009.25.3641.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2057_CR41","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1158\/1535-7163.MCT-10-1100","volume":"10","author":"A Shrivastava","year":"2011","unstructured":"Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther. 2011;10(7):1161\u201372. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-1100.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2057_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113203","volume":"12","author":"ES Seltzer","year":"2020","unstructured":"Seltzer ES, Watters AK, MacKenzie D, Granat LM, Zhang D. Cannabidiol (CBD) as a promising anti-cancer drug. Cancers (Basel). 2020;12(11):3203. https:\/\/doi.org\/10.3390\/cancers12113203.","journal-title":"Cancers (Basel)"},{"key":"2057_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2022.110487","volume":"101","author":"A Acosta-Casique","year":"2023","unstructured":"Acosta-Casique A, et al. ERK activation modulates invasiveness and reactive oxygen species (ROS) production in triple negative breast cancer cell lines. Cell Signal. 2023;101:110487. https:\/\/doi.org\/10.1016\/j.cellsig.2022.110487.","journal-title":"Cell Signal"},{"issue":"1","key":"2057_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-022-00110-2","volume":"3","author":"Q Li","year":"2022","unstructured":"Li Q, Li Z, Luo T, Shi H. Targeting the PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways for cancer therapy. Mol Biomed. 2022;3(1):47. https:\/\/doi.org\/10.1186\/s43556-022-00110-2.","journal-title":"Mol Biomed"},{"key":"2057_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115784","volume":"168","author":"X Li","year":"2023","unstructured":"Li X, et al. Bruceine A: suppressing metastasis via MEK\/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer. Biomed Pharmacother. 2023;168:115784. https:\/\/doi.org\/10.1016\/j.biopha.2023.115784.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"2057_CR46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/73171","volume":"6","author":"I Galve-Roperh","year":"2000","unstructured":"Galve-Roperh I, S\u00e1nchez C, Cort\u00e9s ML, del G\u00f3mez Pulgar T, Izquierdo M, Guzm\u00e1n M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med. 2000;6(3):313\u20139. https:\/\/doi.org\/10.1038\/73171.","journal-title":"Nat Med"},{"issue":"1","key":"2057_CR47","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47\u201359. https:\/\/doi.org\/10.1038\/nrm2308.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"2057_CR48","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1124\/mol.106.023937","volume":"70","author":"RJ McKallip","year":"2006","unstructured":"McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M. Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol. 2006;70(3):897\u2013908. https:\/\/doi.org\/10.1124\/mol.106.023937.","journal-title":"Mol Pharmacol"},{"issue":"18","key":"2057_CR49","doi-asserted-by":"publisher","first-page":"29668","DOI":"10.18632\/oncotarget.9408","volume":"8","author":"M Elbaz","year":"2017","unstructured":"Elbaz M, Ahirwar D, Ravi J, Nasser MW, Ganju RK. Novel role of cannabinoid receptor 2 in inhibiting EGF\/EGFR and IGF-I\/IGF-IR pathways in breast cancer. Oncotarget. 2017;8(18):29668\u201378. https:\/\/doi.org\/10.18632\/oncotarget.9408.","journal-title":"Oncotarget"},{"key":"2057_CR50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-biochem-051710-134100","volume":"81","author":"A Shilatifard","year":"2012","unstructured":"Shilatifard A. The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. Annu Rev Biochem. 2012;81:65\u201395. https:\/\/doi.org\/10.1146\/annurev-biochem-051710-134100.","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"2057_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","volume":"150","author":"MA Dawson","year":"2012","unstructured":"Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12\u201327. https:\/\/doi.org\/10.1016\/j.cell.2012.06.013.","journal-title":"Cell"},{"issue":"6","key":"2057_CR52","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S1097-2765(03)00477-5","volume":"12","author":"AHFM Peters","year":"2003","unstructured":"Peters AHFM, et al. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol Cell. 2003;12(6):1577\u201389. https:\/\/doi.org\/10.1016\/S1097-2765(03)00477-5.","journal-title":"Mol Cell"},{"issue":"5595","key":"2057_CR53","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1126\/science.1076997","volume":"298","author":"R Cao","year":"2002","unstructured":"Cao R, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing. Science. 2002;298(5595):1039\u201343. https:\/\/doi.org\/10.1126\/science.1076997.","journal-title":"Science"},{"issue":"7330","key":"2057_CR54","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343\u20139. https:\/\/doi.org\/10.1038\/nature09784.","journal-title":"Nature"},{"issue":"7","key":"2057_CR55","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ng.154","volume":"40","author":"Z Wang","year":"2008","unstructured":"Wang Z, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40(7):897\u2013903. https:\/\/doi.org\/10.1038\/ng.154.","journal-title":"Nat Genet"},{"issue":"1","key":"2057_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-13-424","volume":"13","author":"K Karmodiya","year":"2012","unstructured":"Karmodiya K, Krebs AR, Oulad-Abdelghani M, Kimura H, Tora L. H3K9 and H3K14 acetylation co-occur at many gene regulatory elements, while H3K14ac marks a subset of inactive inducible promoters in mouse embryonic stem cells. BMC Genomics. 2012;13(1):424. https:\/\/doi.org\/10.1186\/1471-2164-13-424.","journal-title":"BMC Genomics"},{"issue":"4","key":"2057_CR57","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/ng1531","volume":"37","author":"MF Fraga","year":"2005","unstructured":"Fraga MF, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37(4):391\u2013400. https:\/\/doi.org\/10.1038\/ng1531.","journal-title":"Nat Genet"},{"key":"2057_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01685","author":"C Yang","year":"2020","unstructured":"Yang C, et al. FGF18 inhibits clear cell renal cell carcinoma proliferation and invasion via regulating epithelial-mesenchymal transition. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.01685.","journal-title":"Front Oncol"},{"issue":"35","key":"2057_CR59","doi-asserted-by":"publisher","first-page":"47869","DOI":"10.1007\/s11356-021-15594-8","volume":"28","author":"N El Omari","year":"2021","unstructured":"El Omari N, et al. Anticancer mechanisms of phytochemical compounds: focusing on epigenetic targets. Environ Sci Pollut Res. 2021;28(35):47869\u2013903. https:\/\/doi.org\/10.1007\/s11356-021-15594-8.","journal-title":"Environ Sci Pollut Res"},{"issue":"5","key":"2057_CR60","first-page":"589","volume":"2","author":"Y Chervona","year":"2012","unstructured":"Chervona Y, Costa M. Histone modifications and cancer: biomarkers of prognosis? Am J Cancer Res. 2012;2(5):589\u201397.","journal-title":"Am J Cancer Res"},{"issue":"7","key":"2057_CR61","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","volume":"163","author":"L De Petrocellis","year":"2011","unstructured":"De Petrocellis L, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479\u201394. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01166.x.","journal-title":"Br J Pharmacol"},{"key":"2057_CR62","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","volume":"175","author":"S Pisanti","year":"2017","unstructured":"Pisanti S, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017;175:133\u201350. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.041.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"2057_CR63","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/tcrm.s1928","volume":"4","author":"EB Russo","year":"2008","unstructured":"Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2008;4(1):245\u201359. https:\/\/doi.org\/10.2147\/tcrm.s1928.","journal-title":"Ther Clin Risk Manag"},{"key":"2057_CR64","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bcp.2018.06.025","volume":"157","author":"S Blasco-Benito","year":"2018","unstructured":"Blasco-Benito S, et al. Appraising the \u2018entourage effect\u2019: antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochem Pharmacol. 2018;157:285\u201393. https:\/\/doi.org\/10.1016\/j.bcp.2018.06.025.","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2057_CR65","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1158\/1535-7163.MCT-10-0688","volume":"10","author":"S Torres","year":"2011","unstructured":"Torres S, et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011;10(1):90\u2013103. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0688.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2057_CR66","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1124\/dmd.121.000530","volume":"49","author":"S Nasrin","year":"2021","unstructured":"Nasrin S, Watson CJW, Bardhi K, Fort G, Chen G, Lazarus P. Inhibition of UDP-glucuronosyltransferase enzymes by major cannabinoids and their metabolites. Drug Metab Dispos. 2021;49(12):1081\u20139. https:\/\/doi.org\/10.1124\/dmd.121.000530.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"2057_CR67","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/onco4040021","volume":"4","author":"G Nahler","year":"2024","unstructured":"Nahler G. Phytocannabinoids as chemotherapy adjuncts\u2014a review for users. Onco. 2024;4(4):287\u2013321. https:\/\/doi.org\/10.3390\/onco4040021.","journal-title":"Onco"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02057-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-026-02057-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-026-02057-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:57:30Z","timestamp":1788353850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-026-02057-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2057"],"URL":"https:\/\/doi.org\/10.1007\/s13346-026-02057-1","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Animal Care and Use Committee at Florida A&M University, Tallahassee, FL, USA, (protocol code 023\u201302 and Jan 20, 2023; protocol approval no. 023\u201313, approval date: May 10, 2022).","order":2,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the authors used ChatGPT 4.0 in order to improve language and readability. After using this tool, the authors reviewed and edited the content as needed and takes full responsibility for the content of the publication.","order":3,"name":"Ethics","label":"Declaration of generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}